Evrys Bio
Doylestown
About Evrys Bio
Evrys Bio was founded on breakthrough discoveries made at Princeton University. Whereas immuno-oncology drugs engage the patient’s immune system to fight cancer, Evrys Bio antivirals engage the cell’s intrinsic immunity to defend against infection. Evrys Bio’s vision is to develop first-in-class antivirals that are safe, address the problem of acquired drug-resistance, and provide unique broad-spectrum treatment options. This will transform the practice of medicine by addressing the infectious disease condition holistically as opposed to targeting a specific virus-type.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: $10K – $50K
- Total funding: $34.8M
- Funding stage: Early Stage Venture
- Last round: Grant (Jul 2021)
- Website: evrysbio.com
- Phone: 609-874-9013
Industries & Categories
Biotechnology, Health Care, Pharmaceutical, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/evrys-bio-50942 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.